ArticleThe Journal of experimental medicine2006
Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE.
Article in The Journal of experimental medicine, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 250 citations in OpenAlex.
- The Dual Role of Preexisting Immunity in Influenza: Protective Recall Versus Constraint of Novel Responses.Immunological reviews · 2026Review
- Dysregulation of anti-Ro60 B cell autoreactivity in systemic lupus erythematosus.bioRxiv : the preprint server for biology · 2026Article
- A HiBiT-tagged pseudovirus-like particle platform for safe, rapid quantification of virus neutralization and antibody-dependent enhancement.Journal of virology · 2025Article
- Circulating B cells display differential immune regulatory molecule expression in granulomatosis with polyangiitis.Clinical and experimental immunology · 2025Article
- Review
- From promise to practice: evaluating the clinical impact of FcRn inhibition in IgG-mediated autoimmune rheumatic diseases.Frontiers in immunology · 2025Review
- B cell function in patients with systemic lupus erythematosus is regulated by the upregulation of JunD.Heliyon · 2024Article
- Current development of Fc gamma receptors (FcγRs) in diagnostics: a review.Molecular biology reports · 2024Review
- Serum immunoglobulin and the threshold of Fc receptor-mediated immune activation.Biochimica et biophysica acta. General subjects · 2023Review
- Understanding humoral immunity and multiple sclerosis severity in Black, and Latinx patients.Frontiers in immunology · 2023Review
- B cell activation via immunometabolism in systemic lupus erythematosus.Frontiers in immunology · 2023Review
- Article
- Review
- FcγRIIB regulates autoantibody responses by limiting marginal zone B cell activation.The Journal of clinical investigation · 2022Article
- Increased levels of a pro-inflammatory IgG receptor in the midbrain of people with schizophrenia.Journal of neuroinflammation · 2022Article
- B Cell Aberrance in Lupus: the Ringleader and the Solution.Clinical reviews in allergy & immunology · 2022Review
- CD11cFrontiers in immunology · 2022Article
- Targeting B cells in the pre-phase of systemic autoimmunity globally interferes with autoimmune pathology.iScience · 2021Article
- Fc Receptor Variants and Disease: A Crucial Factor to Consider in the Antibody Therapeutics in Clinic.International journal of molecular sciences · 2021Review
- Inhibition of B cell activation followingJournal of translational autoimmunity · 2021Article
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The inappropriate expansion and activation of autoreactive memory B cells and plasmablasts contributes to loss of self-tolerance in systemic lupus erythematosus (SLE). Defects in the inhibitory Fc receptor, FcgammaRIIB, have been shown to contribute to B cell activation and autoimmunity in several mouse models of SLE. In this paper, we demonstrate that expression of FcgammaRIIB is routinely up-regulated on memory B cells in the peripheral blood of healthy controls, whereas up-regulation of FcgammaRIIB is considerably decreased in memory B cells of SLE patients. This directly correlates with decreased FcgammaRIIB-mediated suppression of B cell receptor-induced calcium (Ca2+) response in those B cells. We also found substantial overrepresentation of African-American patients among those who failed to up-regulate FcgammaRIIB. These results suggest that the inhibitory receptor, FcgammaRIIB, may be impaired at a critical checkpoint in SLE in the regulation of memory B cells; thus, FcgammaRIIB represents a novel target for therapeutic interventions in this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.